EP0661996A4 - Mhc subunit conjugates useful in ameliorating deleterious immune responses. - Google Patents

Mhc subunit conjugates useful in ameliorating deleterious immune responses.

Info

Publication number
EP0661996A4
EP0661996A4 EP93900577A EP93900577A EP0661996A4 EP 0661996 A4 EP0661996 A4 EP 0661996A4 EP 93900577 A EP93900577 A EP 93900577A EP 93900577 A EP93900577 A EP 93900577A EP 0661996 A4 EP0661996 A4 EP 0661996A4
Authority
EP
European Patent Office
Prior art keywords
immune responses
deleterious immune
conjugates useful
mhc subunit
ameliorating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP93900577A
Other languages
German (de)
French (fr)
Other versions
EP0661996A1 (en
Inventor
Bishwajit Nag
Brian R Clark
Somesh D Sharma
Harden M Mcconnel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anergen Inc
Original Assignee
Anergen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anergen Inc filed Critical Anergen Inc
Publication of EP0661996A1 publication Critical patent/EP0661996A1/en
Publication of EP0661996A4 publication Critical patent/EP0661996A4/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Rehabilitation Therapy (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP93900577A 1991-11-19 1992-11-18 Mhc subunit conjugates useful in ameliorating deleterious immune responses. Ceased EP0661996A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79393891A 1991-11-19 1991-11-19
US793938 1991-11-19
PCT/US1992/010031 WO1993009810A1 (en) 1991-11-19 1992-11-18 Mhc subunit conjugates useful in ameliorating deleterious immune responses

Publications (2)

Publication Number Publication Date
EP0661996A1 EP0661996A1 (en) 1995-07-12
EP0661996A4 true EP0661996A4 (en) 1997-05-21

Family

ID=25161218

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93900577A Ceased EP0661996A4 (en) 1991-11-19 1992-11-18 Mhc subunit conjugates useful in ameliorating deleterious immune responses.

Country Status (5)

Country Link
EP (1) EP0661996A4 (en)
JP (1) JPH07501526A (en)
AU (1) AU3220693A (en)
CA (1) CA2123228A1 (en)
WO (1) WO1993009810A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69232875T2 (en) * 1991-04-23 2003-08-21 Anergen, Inc. MHC conjugates to improve autoimmunity.
AU3423293A (en) * 1991-12-19 1993-07-19 Baylor College Of Medicine Pva or peg conjugates of peptides for epitope-specific immunosuppression
EP1138766A3 (en) * 1992-10-15 2003-05-02 Toray Industries, Inc. Process for preparing major histocompatibility antigen class II protein and materials having the same immobilized thereon
US6045796A (en) * 1992-12-17 2000-04-04 Anergen, Inc. Vaccination with peptide of MHC class II molecules for treatment of autoimmune disease
US5820866A (en) * 1994-03-04 1998-10-13 National Jewish Center For Immunology And Respiratory Medicine Product and process for T cell regulation
WO1995027505A1 (en) * 1994-04-12 1995-10-19 Biomira, Inc. Cellular immune response-specific antigens and uses therefor
US7074904B2 (en) 1994-07-29 2006-07-11 Altor Bioscience Corporation MHC complexes and uses thereof
EP0776339B2 (en) * 1994-07-29 2010-01-20 Sunol Molecular Corporation Mhc complexes and uses thereof
AU4278296A (en) * 1994-10-25 1996-05-15 Immulogic Pharmaceutical Corporation Compositions and treatment for multiple sclerosis
US6056952A (en) * 1995-08-30 2000-05-02 The United States Of America As Represented By The Department Of Health And Human Services Selective elimination of T cells that recognize specific preselected targets
CA2237114A1 (en) * 1995-11-07 1997-05-15 Kaneka Corporation Autoantigens
US5869270A (en) * 1996-01-31 1999-02-09 Sunol Molecular Corporation Single chain MHC complexes and uses thereof
US6232445B1 (en) 1997-10-29 2001-05-15 Sunol Molecular Corporation Soluble MHC complexes and methods of use thereof
JP7270946B2 (en) * 2017-08-08 2023-05-11 国立大学法人浜松医科大学 Agent for treatment or prevention of autoimmune disease
JPWO2019054409A1 (en) * 2017-09-12 2020-11-12 国立大学法人北海道大学 Screening methods and screening kits for substances that interact with HLA proteins

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989012459A1 (en) * 1988-06-23 1989-12-28 Biospan Corporation Mhc-mediated toxic conjugates useful in ameliorating autoimmunity
WO1990014835A1 (en) * 1989-05-31 1990-12-13 Scripps Clinic And Research Foundation Method to treat rheumatoid arthritis
WO1991014701A1 (en) * 1990-03-21 1991-10-03 The Board Of Trustees Of The Leland Stanford Junior University Improved major histocompatibility complex (mhc) molecules

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260422A (en) * 1988-06-23 1993-11-09 Anergen, Inc. MHC conjugates useful in ameliorating autoimmunity
US5130297A (en) * 1988-06-23 1992-07-14 Anergen, Inc. Conjugates useful in ameliorating autoimmunity MHC-II-peptide

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989012459A1 (en) * 1988-06-23 1989-12-28 Biospan Corporation Mhc-mediated toxic conjugates useful in ameliorating autoimmunity
WO1990014835A1 (en) * 1989-05-31 1990-12-13 Scripps Clinic And Research Foundation Method to treat rheumatoid arthritis
WO1991014701A1 (en) * 1990-03-21 1991-10-03 The Board Of Trustees Of The Leland Stanford Junior University Improved major histocompatibility complex (mhc) molecules

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PASSMORE ET AL: "PREPARATIVE-SCALE PURIFICATION AND CHARACTERIZATION OF MHC CLASS II MONOMERS", JOURNAL OF IMMUNOLOGICAL METHODS, vol. 155, no. 2, 5 November 1992 (1992-11-05), pages 193 - 200, XP002026330 *
See also references of WO9309810A1 *

Also Published As

Publication number Publication date
WO1993009810A1 (en) 1993-05-27
CA2123228A1 (en) 1993-05-27
JPH07501526A (en) 1995-02-16
AU3220693A (en) 1993-06-15
EP0661996A1 (en) 1995-07-12

Similar Documents

Publication Publication Date Title
AU1914492A (en) MHC conjugates useful in ameliorating autoimmunity
GB2255395B (en) Force transfer device
GB2253528B (en) Improvements in connectors
EP0461400A3 (en) Text processing device
ZA929335B (en) Device.
EP0661996A4 (en) Mhc subunit conjugates useful in ameliorating deleterious immune responses.
EP0510643A3 (en) Charging member and device using the same
GB2245340B (en) Improvements in frictional resistance couplings
EP0542383A3 (en) Compression device.
HK52995A (en) Connector device.
AU112636S (en) Armchair
EP0630255A4 (en) Mhc conjugates useful in ameliorating autoimmunity.
HK52695A (en) Conducting connector device.
GB2242355B (en) Seat slide device
EP0468714A3 (en) Peptide-polysaccharide-protein conjugate vaccines
AU112867S (en) An armchair
GB9003498D0 (en) Seat device
ZA926056B (en) Penile support arrangement and member.
GB2258646B (en) Universal sports spectator carrybag, seat and stepstool
Niekus Bedload waves in a small ephemeral sand-bed channel
GB2238959B (en) Antigen and conjugates thereof for suppressing immune response
NZ238953A (en) Antibody-superantigen conjugates
IE900092L (en) Beverage infusion device
EP0534131A3 (en) Mos technique in soi technique
GB9218253D0 (en) Improvements in fuels

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19940608

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19970404

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL SE

17Q First examination report despatched

Effective date: 19981111

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 39/00 A, 7A 61K 39/385 B, 7C 07K 17/02 B, 7G 01N 33/53 B

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 39/00 A, 7A 61K 39/385 B, 7C 07K 17/02 B, 7G 01N 33/53 B

RTI1 Title (correction)

Free format text: THERAPEUTIC CONJUGATES COMPRISING A MHC CLASS II SUBUNIT COMPONENT AND MBP PEPTIDES

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 39/00 A, 7A 61K 39/385 B, 7C 07K 17/02 B, 7G 01N 33/53 B

RTI1 Title (correction)

Free format text: THERAPEUTIC CONJUGATES COMPRISING A MHC CLASS II SUBUNIT COMPONENT AND MBP PEPTIDES

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20011214